Overview

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Status:
Completed
Trial end date:
2019-10-29
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine the tolerability and safety of ATV-PG + AQ, ATV-PG + AQ placebo, ATV-PG placebo + AQ, and ATV-PG placebo + AQ placebo administered once daily for 3 days to healthy adult male and female subjects.This study in healthy adults is the first step towards establishing the tolerability and safety of the approved doses of ATV-PG and AQ when co-administered. If considered acceptable based on the findings of this study, the tolerability, safety and PE will subsequently be assessed, within the target geographical areas.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborator:
Richmond Pharmacology Limited
Treatments:
Amodiaquine
Atovaquone
Atovaquone, proguanil drug combination
Proguanil